The assessment of antichymotrypsin in cancer monitoring.

Abstract

A comparative study of serum antichymotrypsin, acid glycoprotein and antitrypsin levels has been made in various cancers. Antichymotrypsin (ACT) shows a non-specific elevation in metastatic cancer, and the response reflects tumour progression in a similar fashion to the other two acute phase reactant proteins. The main advantage of ACT as a marker appears to be its Normal distribution in health, and lack of phenotypic variation.